Board of Directors
Mr. Michael Heffernan
Mr. Heffernan is Co-Founder, President, & CEO of Collegium Pharmaceutical Inc.
Mr. Heffernan is the chairman of Ocata Therapeutics Inc.
Mette Kirstine Agger
Ms. Agger has been a Board Member of Veloxis since April 2010. Ms. Agger is Managing Partner of Lundbeckfond Ventures, a company fully owned by the Lundbeck Foundation. She joined the company on September 1, 2009.
Ms. Agger is a board member of Klifo A/S, PsiOxus Therapeutics Ltd, Cydan LLC, scPharmaceuticals LLC, Thesan Pharamceuticals Inc, and Vtesse Pharma.
Mr. Götzsche has been a Board Member of Veloxis since April 2008. Mr. Götzsche is Executive Vice President and Chief Financial Officer at H. Lundbeck. He joined Lundbeck on September 1, 2007.
Mr. Götzsche is a board member of Rosborg Møbler A/S.
Dr. Lars Viksmoen, MD
Dr. Paul K. Wotton, PhD
Dr. Wotton is President and CEO of Sigilon Inc. He was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through a take-over by Astellas Pharma, Inc., in a US$379 million all cash transaction. Prior to Ocata, Dr. Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS), since October, 2008. Prior to joining Antares, Dr. Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Earlier in his career he held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton is a member of the boards of Vericel Corporation (NASDAQ:VCEL) and Cynata Therapeutics (ASX:CYP) and also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. Dr. Wotton received his Ph.D. in pharmaceutical sciences from the University of Nottingham. In 2014 he was named New Jersey EY Entrepreneur of the Year in Life Sciences.
Robert S. Radie
Mr. Radie is president, chief executive officer and a member of Egalet’s board of directors and has been since March 2012. Mr. Radie has had a successful career with more than three decades in the industry and has been responsible for the sale of five companies. In 2005, Mr. Radie led the sale of Vicuron Pharmaceuticals to Pfizer for $1.9 billion and most recently he was responsible for the sale of Topaz Pharmaceuticals Inc. to Sanofi Pasteur for an undisclosed amount. Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Prestwick Pharmaceuticals, Inc., Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and served as a director of Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014, when a majority of Affinium's assets were acquired by a third party. Mr. Radie began his career in the life sciences at Eli Lilly and Company where he worked for 18 years in sales and marketing positions with increasing levels of responsibility. Mr. Radie serves on the board of Paratek Pharmaceuticals, a biopharmaceutical company, Pennsylvania Bio, an industry group supporting Pennsylvania life sciences companies, Veloxis, a public commercial-stage company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie received his B.S. in chemistry from Boston College.
Alastair McEwan, EVP, COO
Phone: +1 732 321 3200
BUSINESS DEVELOPMENT CONTACT:
Alastair McEwan, EVP, COO